Iovance Biotherapeutics to Host Conference Call and Webcast


SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) – Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), an advanced-stage biotechnology company developing novel T-cell-based cancer immunotherapies, announced that management will hold a conference call and live audio webcast to discuss recent clinical data for LN-145 TIL therapy in non-small cell lung cancer today at 4:30 p.m. ET.

To participate in the conference call, please dial 1-844-646-4465 (national) or 1-615-247-0257 (international) and provide access code 2989712. The live webcast is available in the section Investors from the Company’s website. website at www.iovance.com. The archived webcast will also be available for one year in the Investors section at www.iovance.com.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies widely available for the treatment of patients with solid tumors and blood cancers. Tumor-infiltrating lymphocyte therapy (TIL) uses the patient’s own immune cells to attack the cancer. TIL cells are extracted from a patient’s tumor tissue, multiplied by a proprietary process, and injected back into the patient. Upon infusion, TILs reach tumor tissue, where they attack cancer cells. The company has completed the assay in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company’s TIL therapy is being investigated in a registration support study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in early stage cancers in combination with currently approved treatments, and to study peripheral ovance T cell (PBL) therapy for blood cancers. For more information, please visit www.iovance.com.

CONTACTS

Iovance Biotherapeutics, Inc:
Sara Pellegrino, CRI
Vice-President, Investor Relations and Public Relations
650-260-7120 ext. 264
[email protected]

Solebury Trout:
Zara Lockshin (media)
646.378.2960
[email protected]



Source link